{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bellone S"],"funding":["Stand Up To Cancer","NCATS NIH HHS","NIH Clinical Center","NCI NIH HHS","National Research Foundation of Korea","Fondazione Guido Berlucchi","Honorable Tina Brozman Foundation","Merck","Gilead Sciences"],"pagination":["1206-1218"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9465822"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["128(6)"],"pubmed_abstract":["Background
Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) is a biomarker for responses to immune checkpoint inhibitors (ICIs). Whether mechanisms underlying microsatellite instability alter responses to ICIs is unclear. This article reports data from a prospective phase 2 pilot study of pembrolizumab in patients with recurrent MSI-H endometrial cancer (EC) analyzed by whole exome sequencing (WES) and potential mechanisms of primary/secondary ICI resistance (NCT02899793).Methods
Patients with measurable MSI-H/dMMR EC confirmed by polymerase chain reaction/immunohistochemistry were evaluated by WES and received 200 mg of pembrolizumab every 3 weeks for ≤2 years. The primary end point was the objective response rate (ORR). Secondary end points includ"],"journal":["Cancer"],"pubmed_title":["A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability."],"pmcid":["PMC9465822"],"funding_grant_id":["CA‐16359","U01 CA176067","P30 CA008748","CA-16359","UL1 TR001863","NRF-2019R1A4A102900","P30 CA016359","U01 CA176067‐01"],"pubmed_authors":["Buza N","Dong W","Roque DM","Clark M","Azodi M","Guglielmi A","Lee J","Zammataro L","Siegel ER","Silasi DA","Elvin JA","Choi J","Huang GS","Bonazzoli E","Santin AD","Zeybek B","Iwasaki A","Altwerger G","Zaidi S","Ratner E","Damast S","Nagarkatti N","Bellone S","Hui P","Alexandrov LB","Menderes G","Harold JA","Song E","Tymon-Rosario JR","Mauricio D","Schwartz PE","Andikyan V","Kong Y"],"additional_accession":[]},"is_claimable":false,"name":"A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.","description":"Background
Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) is a biomarker for responses to immune checkpoint inhibitors (ICIs). Whether mechanisms underlying microsatellite instability alter responses to ICIs is unclear. This article reports data from a prospective phase 2 pilot study of pembrolizumab in patients with recurrent MSI-H endometrial cancer (EC) analyzed by whole exome sequencing (WES) and potential mechanisms of primary/secondary ICI resistance (NCT02899793).Methods
Patients with measurable MSI-H/dMMR EC confirmed by polymerase chain reaction/immunohistochemistry were evaluated by WES and received 200 mg of pembrolizumab every 3 weeks for ≤2 years. The primary end point was the objective response rate (ORR). Secondary end points includ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-05-10T06:52:11.991Z","creation":"2025-02-19T03:26:45.484Z"},"accession":"S-EPMC9465822","cross_references":{"pubmed":["34875107"],"doi":["10.1002/cncr.34025"]}}